GSK's antibiotic drug gepotidacin gets priority review by FDA
ReutersAug 11, 2025 6:10 AM
Aug 11 (Reuters) - British drugmaker GSK GSK.L said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral treatment of uncomplicated urogenital gonorrhoea.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
MGM Resorts International (MGM): Huge Potential in Online Gaming
TradingKey - MGM seems undervalued, as the market does not appreciate the potential of the company’s online betting business, which has a very high growth at 25% and real possibility to have much higher profitability than the traditional on-ground casino business.TradingKey
6 hours ago
U.S. Stock Strategy: The Rapid Development of AI Signals a Promising Future
TradingKey - Since Trump announced a 90-day suspension of the "reciprocal tariffs" imposed on certain countries on 9 April this year, all three major U.S. stock indices have recorded significant gains. Looking ahead, against the backdrop of easing global trade frictions.TradingKey
7 hours ago
Size Matters? Royal Caribbean Cruises Don’t Think So
TradingKey - Royal Caribbean Group (RCL), as the world’s second-largest cruise operator, demonstrates industry-leading recovery and competitive strength in the post-pandemic era through robust revenue growth (18.6% increase in 2024, with net income surging 70.6%), exceptional operational efficiencyTradingKey
10 hours ago
China July Inflation Commentary: CPI Exceeds Expectations
TradingKey - On 9 August 2025, China's National Bureau of Statistics released inflation data for July. The Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing the previous month's 0.1% decline, while remaining unchanged year-on-year. Core CPI increased by 0.8% year-on-year.TradingKey
17 hours ago
U.S. CPI Preview: Bullish Outlook for U.S. Stocks Continues
TradingKey - On 12 August 2025, the U.S. will release its July CPI data. Market consensus forecasts a year-over-year headline CPI increase of 2.8% and a core CPI rise of 3%, both up 0.1 percentage points from June. We align with these widely held market expectations. Breaking it down by category...TradingKey
17 hours ago
